Emerges as County’s First New York State Designated Regional Stroke Center
Stroke is the #1 cause of disability and the #5 cause of death in the U.S. Every 40 seconds, someone in the U.S. has a stroke and nearly 800,000 suffer a new or recurrent stroke each year. With stroke, medical experts agree – “Time is brain.”
So, to meet the increasing demand for immediate, life-saving care in Westchester, White Plains Hospital is expanding its already robust stroke treatment program to now include two highly specialized physicians.
Boris Chulpayev, M.D., is leading the expansion of clinical services for patients at The Ruth & Jerome A. Siegel Stroke Center at White Plains Hospital, Westchester County’s first New York State-designated Regional Stroke Center. Both he and his partner, Holly Hensley, M.D.—are neurohospitalists skilled at managing the care of inpatients who have suffered from or who are at risk for a stroke, or who have other neurologic disorders.
“Our patients now have an even higher degree of specialized care to protect them from the damaging effects of stroke,” said Michael Palumbo, M.D., Chief medical Officer and Executive Vice President at White Plains Hospital. “As we expand our Hospital’s advanced neurology capabilities, Dr. Chulpayev and Dr. Hensley will stay at the forefront of the latest evidence-based practices to ensure that our patients receive the highest quality of stroke care.” For the past 13 years, White Plains Hospital has been recognized with the American Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke Gold Plus Quality Achievement Award for success in ensuring that stroke patients receive the most appropriate treatment according to nationally recognized, research-based guidelines.
In 2018, White Plains Hospital also made the Association’s Target: StrokeSM Elite Honor Roll for meeting stroke quality measures that reduce the time between a patient’s arrival at the Hospital and treatment with the clot-buster tissue plasminogen activator, or tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke.If administered within the first three hours after the start of stroke symptoms, tPA has been shown to significantly reduce the effects of stroke and the chance of permanent disability.
For additional info, visit wphospital.org
